A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors

Annals of Oncology

Volumn 7, Issue 10, 1996, Pages 1015-1021

  Bokemeyer, C ^a   Kohrmann O ^b   Tischler, J ^c   Weissbach L ^d   Rath U ^e   Haupt, A ^a   Schoffski P ^f   Harstrick, A ^g   Schmoll, H J ^h  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c KLINIKUM MINDEN   (Germany)

^d VIVANTES KLINIKUM AM URBAN   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

carboplatin; chemotherapy; cisplatin; Indiana University classification; prognostic factors; randomized study; testicular cancer; toxicity

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NON SEMINOMATOUS GERMINOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TESTIS CANCER;

EID: 0030477951     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010493     Document Type: Article

References (24)

1. Einhorn LH. Treatment of testicular cancer: A new and improved model. J Clin Oncol 1990; 8: 1777-81.
2. Bosl GJ, Geller NL, Cirricone C et al. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 1983; 43: 3403-7.
3. Vogelzang NJ. Prognostic factors in metastatic testicular cancer. Int J Androl 1987; 10: 225-37.
4. Birch R, Williams S. Cone A et al. Prognostic factors for favourable outcome in disseminated germ cell tumors. J Clin Oncol 1986; 4: 400-7.
5. Williams S, Birch R, Einhorn LH et al. Treatment of dissiminated germ cell tumors with cisplatin, bleomycin and either vinblastinoretoposide.N Engl J Med 1987; 316(23): 1435-40.
6. Einhorn LH, Wiliams SD, Loehrer PJ et al. A comparison of four versus three courses of cisplatin, VP-16 and bleomycin in favorable prognosis disseminated germ cell tumors. J Clin Oncol 1989; 7: 387-91.
7. Loehrer PJ Sr, Johnson D, Elson P et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial. J Clin Oncol 1995; 13: 470-6.
8. Vermorken JB, Bokkel Huinink ten WW, Eisenhauer EA et al. Carboplatin versus cisplatin. Ann Oncol 1993; 4 (Suppl 4): 41-8.
9. O'Reilly SM, Rustin GJS, Smith DB, Newlands ES. Single agent activity of carboplatin in patient with previously untreated non-seminomatous germ cell tumours. Ann Oncol 1992; 3: 163-4.
10. Horwich A, Dearnaley DP, Nicholls J et al. Effectiveness of carboplatin, etoposide and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors. J Clin Oncol 1991; 9: 62-9.
11. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-56.
12. Bajorin DF, Sarosdy MF, Pfister DG et al. Randomized trial of etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study. J Clin Oncol 1993; 11: 598-606.
13. Tjulandin SA, Garin AM, Mescheryakov AA et al. Cisplatinetoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors. Ann Oncol 1993; 4: 633-7.
14. Culine S, Mahjoubi M, Philoppot I, Droz JP. Treatment of good-risk disseminated non-seminomatous germ cell tumours; the less bleomycin, the more cisplatin? Eur J Cancer 1991; 12: 1715 (Letter).
15. Kattan J, Mahjoubi M, Droz JP et al. High failure rate of carboplatin-etoposide combination in good risk non-seminomatous germ cell tumours. Eur J Cancer 1993; 29A: 1504-9.
16. Fish RG, Shelley MD, Griffiths H et al. A dosing scheme for carboplatin in adult cancer patients bases upon pre-infusion renal function and platelet count. Anticancer-Drugs 1994; 5: 527-32.
17. Childs WJ, Nicholls EJ, Horwich A. The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic non-seminomatous germ cell tumours of the testis. Ann Oncol 1992; 3: 291-6.
18. Horwich A, Sleijfer D, Fossa S et al. on behalf of the UK Medical Research Council Testicular Tumour Working Party & EORTC Genito-Urinary Group. A trial of carboplatin-based combination chemotherapy in good prognosis metastatic tes-ticular cancer. Proc Am Soc Clin Oncol 1994; 13: 709 (Abstr).
19. Bokemeyer C, Harstrick A, Schmoll HJ. The use of carboplatin in malignant germ cell tumours. Eur J Cancer 1994, 30A: 721-2.
20. Harstrick A, Caspar J, Guba R et al. Comparison of the antitumor activity of cisplatin, carboplatin and iproplatin against established human testicular cancer cell lines in vivo and in vitro. Cancer 1989; 63: 1079-983.
21. Schmoll HJ, Harstrick A, Bokemeyer C et al. Single-agent carboplalin for advanced seminoma. A phase II study. Cancer 1993; 72: 237-43.
22. Horwich A, Dearnaley DP, Duchesne GM et al. Simple non-toxic treatment of advanced metastatic seminoma with carboplatin. J Clin Oncol 1989; 7: 1150-6.
23. Lampe H, Dearnaley DP, Price A et al. High-dose carboplatin and etoposide for salvage chemotherapy of germ cell tumours. Eur J Cancer 1995, 31 A: 717-23.
24. Nichols CR, Tricot G, Williams S et al. Dose-intensive chemotherapy in refractrory germ cell cancer: A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989; 7: 932-9.